IGHG3 and cancer: Preclinical evaluations demonstrate their ability to activate various T cell subsets, potentially offering enhanced cellular responses in clinical settings (Davari, et al. 2021).Furthermore, cancer vaccines targeting MAGE-A4 or MAGE-A family members, such as the H/K-HELP vaccine, have shown promising efficacy in some patients by stimulating Th1 and Tc1 cell cancer-specific immune responses and inducing IgG1 and IgG3 antibody production.